![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Adis International Limited
Publisher: Adis International
ISSN: 1176-3469
Source: Pharmaceutical & Diagnostic Innovation, Vol.4, Iss.5, 2006-01, pp. : 7-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Hormone-Refractory Prostate Cancer: Where are We Going?
Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer
Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer
Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. :